Cartesian Therapeutics, Inc. (RNAC) News
Follow Cartesian Therapeutics, Inc. (RNAC) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
HC Wainwright & Co. reiterates Buy rating on Cartesian Therapeutics, $25 price target
HC Wainwright & Co. reiterated their Buy rating on Cartesian Therapeutics's stock with a price target of $25.00.The price target implies an upside of 245.3% from the Sep 29 close of $7.24.Key takeaways from the analyst n
EQUITY | Sep 30, 2026, 10:35 AM UTC
L
Cartesian Therapeutics Price Target Maintained With a $40.00/Share by Needham
Ratings actions from Benzinga
NEWS | Sep 29, 2026, 04:51 PM UTC
L
Needham reiterates Buy rating on Cartesian Therapeutics, $40 price target
Needham reiterated their Buy rating on Cartesian Therapeutics's stock with a price target of $40.00.The price target implies an upside of 454.8% from the Sep 28 close of $7.21.Key takeaways from the analyst noteStrong Cl
EQUITY | Sep 29, 2026, 04:41 PM UTC
L
Cartesian Therapeutics reports durable improvements after Descartes-08 retreatment; no new safety signals
Cartesian Therapeutics announced that retreatment with Descartes-08 produced sustained symptom improvements at Month 12 with no new safety signals.Key Highlights:Original SEC Filing: Cartesian Therapeutics, Inc. [ RNAC ]
REGULATION | Sep 29, 2026, 11:43 AM UTC
L
Cartesian Therapeutics, Inc. (RNAC) Posts Positive Descartes-08 Retreatment Data; Phase 3 Topline 1Q27
Cartesian Therapeutics reported additional Descartes-08 retreatment data in MG showing mean MG-ADL reduction of 6.6 points at Month 12, with no new safety signals. Topline data from the Phase 3 AURORA trial are expected
NEWS | Sep 29, 2026, 11:33 AM UTC
L
Cartesian Therapeutics Announces Additional Retreatment Data For Descartes-08 Highlighting Deep And Durable Responses In Patients With Myasthenia Gravis
Cartesian Therapeutics, Inc. NASDAQ:RNAC
NEWS | Sep 29, 2026, 11:32 AM UTC
L
Cartesian Therapeutics grants inducement awards to three new employees
Cartesian Therapeutics (RNAC) announced inducement awards to three new employees, with the company stating the awards were granted on Sept. 4, 2026.
EQUITY | Sep 08, 2026, 11:08 AM UTC
L
RNAC - Cartesian Therapeutics Announces New Employment Inducement Grants
RNAC - Cartesian Therapeutics Announces New Employment Inducement Grants
EQUITY | Sep 08, 2026, 11:00 AM UTC
L
Cartesian Therapeutics management to participate in upcoming investor conferences
Cartesian Therapeutics said management expects to participate in upcoming investor conferences, as part of the company’s planned engagement schedule.
EQUITY | Sep 03, 2026, 11:08 AM UTC
L
RNAC - Cartesian Therapeutics to Participate in Upcoming Investor Conferences
RNAC - Cartesian Therapeutics to Participate in Upcoming Investor Conferences
EQUITY | Sep 03, 2026, 11:00 AM UTC
L
RNAC - Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
RNAC - Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
EARNINGS | Aug 06, 2026, 11:00 AM UTC